Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

19.02.2024

1 Ann Neurol
1 BMC Neurol
1 Can J Neurol Sci
2 J Neuroimmunol
1 J Neurol
1 J Neurol Sci
5 Mult Scler
2 N Engl J Med
3 Neurology
1 PLoS One
1 Proc Natl Acad Sci U S A



    Ann Neurol

  1. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    >> Share


    BMC Neurol

  2. GHAZANFARI HASHEMI M, Talebi V, Abbasi Kasbi N, Abbasi M, et al
    T1 hypointense brain lesions in NMOSD and its relevance with disability: a single institution cross-sectional study.
    BMC Neurol. 2024;24:62.
    >> Share


    Can J Neurol Sci

  3. NOBILE S, Beauchemin P
    Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort.
    Can J Neurol Sci. 2024 Feb 12:1-21. doi: 10.1017/cjn.2024.
    >> Share


    J Neuroimmunol

  4. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
    Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
    J Neuroimmunol. 2024;387:578286.
    >> Share

  5. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
    Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
    J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
    >> Share


    J Neurol

  6. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    >> Share


    J Neurol Sci

  7. BALCOM EF, Smyth P, Kate M, Vu K, et al
    Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
    J Neurol Sci. 2024;458:122913.
    >> Share


    Mult Scler

  8. LANGDON D
    Neuropsychological assessment in MS is outdated and in need for innovation: NO.
    Mult Scler. 2024;30:152-153.
    >> Share

  9. KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
    Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
    >> Share

  10. PATEL S, Rafferty S, Aquino L, Chadha S, et al
    VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
    Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
    >> Share

  11. COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
    Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
    >> Share

  12. HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
    A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial.
    Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
    >> Share


    N Engl J Med

  13. HAUSER SL
    Silencing Immune Dialogue in Multiple Sclerosis.
    N Engl J Med. 2024;390:662-663.
    >> Share

  14. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al
    Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
    N Engl J Med. 2024;390:589-600.
    >> Share


    Neurology

  15. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    >> Share

  16. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    >> Share

  17. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    >> Share


    PLoS One

  18. DADVAR A, Jameie M, Azizmohammad Looha M, Parsaei M, et al
    Potential efficacy of caffeine ingestion on balance and mobility in patients with multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial.
    PLoS One. 2024;19:e0297235.
    >> Share


    Proc Natl Acad Sci U S A

  19. ADAMS C, Manouchehrinia A, Quach HL, Quach DL, et al
    Evidence supports a causal association between allele-specific vitamin D receptor binding and multiple sclerosis among Europeans.
    Proc Natl Acad Sci U S A. 2024;121:e2302259121.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016